Results 91 to 100 of about 1,816 (169)

EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1

AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1. METHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016. We followed them
OHSHIMA, Shigetoshi, Miura, Masato, KURAMITSU, Tomoyuki, FUJISHIMA, Yuukou, WATANABE, Daisuke, NAKANE, Kunio, Goto, Mitsuo, AJIMINE, Takuma, YAGISAWA, Hitoshi, NAKAJIMA, Kou, GOTO, Takashi, IIJIMA, Katsunori, HOSHINO, Takao, Inomata, Masaaki, KOMATSU, Masafumi, FUNAOKA, Masato, Segawa, Daisuke   +16 more
core   +2 more sources

Computer-Aided Prediction of the Interactions of Viral Proteases with Antiviral Drugs: Antiviral Potential of Broad-Spectrum Drugs. [PDF]

Molecules, 2023
Ren P, Li S, Wang S, Zhang X, Bai F.
europepmc   +1 more source

Going Viral: An Investigation into the Chameleonic Behaviour of Antiviral Compounds. [PDF]

Chemistry, 2023
Wieske LHE, Atilaw Y, Poongavanam V, Erdélyi M, Kihlberg J.   +4 more
europepmc   +1 more source

The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis. [PDF]

Front Public Health, 2023
Chen R, Xiong Y, Zeng Y, Wang X, Xiao Y, Zheng Y.   +5 more
europepmc   +1 more source

Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review. [PDF]

Cost Eff Resour Alloc
Jafari M, Mehdizadeh P, Teymourzadeh E, Salesi M, Keshavarz K, Abyazi MA, Heiat M, Alavian SM.   +7 more
europepmc   +1 more source

Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study. [PDF]

Medicine (Baltimore)
Sung BR, Shim SG, Kim KM, Lee JW, Kim JY, Lee BK, Jun CH, Kwan BS.   +7 more
europepmc   +1 more source

IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies. [PDF]

Nat Commun
Domizi P, Sarno J, Jager A, Merchant M, Pacheco KZB, Yamada-Hunter SA, Rotiroti MC, Liu Y, Baskar R, Reynolds WD, Sworder BJ, Sahaf B, Bendall SC, Mullighan CG, Alizadeh AA, Leahy AB, Myers RM, Yates B, Wang HW, Shah NN, Majzner RG, Mackall CL, Mackall CL, Grupp SA, Barrett DM, Sotillo E, Davis KL.   +26 more
europepmc   +1 more source

Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study. [PDF]

Medicina (Kaunas), 2023
Yoon JH, Kim SE, Cho SH, Kim GA, Park Y, Park JW, Kang SH, Lee YS, Kim JH.   +8 more
europepmc   +1 more source

Succesful treatment of chronic hepatitis C virus infection with daclatasvir and asunaprevir in a transfusion dependent thalassaemia patient

, 2016
Thalassaemia is one of the most common inherited hemoglobinopathies that is characterized with defective hemoglobin synthesis and ineffective erythropoiesis. Chronic transfusion therapy which increases the risk of hepatitis C virus (HCV) infection is the
ÖZTÜRK, ÖMER, KÖKLÜ, SEYFETTİN, Aksoy, Evrim Kahramanoglu, Tseveldorj, Nomingerel, KÖKLÜ, HAYRETDİN   +4 more
core  

ADNP regulates chromatin architecture and lineage fidelity during neural differentiation. [PDF]

PLoS Genet
Wulfridge P, Rell N, Doherty J, Fang KC, Lynskey ML, Sarma K.   +5 more
europepmc   +1 more source